New approach could expand CAR T therapy from blood cancers to solid tumors

AI Summary

A new combined approach involving CAR T cell immunotherapy and targeted radiopharmaceuticals shows promising tumor regression in preclinical models of neuroblastoma. This advancement could extend CAR T therapy from blood cancers to solid tumors.

Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that combining CAR T cell immunotherapy with a targeted radiopharmaceutical significantly improved tumor regression in preclinical models of neuroblastoma, a rare and aggressive cancer that usually forms in nerve tissue outside the brain and primarily affects children. The findings were published in Cell Reports Medicine.